| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Section of Experimental Pathology, Department of Pathology, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Texas Medical Center, Houston, Texas 77030 [D. L. S., F. F. B.], and Institute of Occupational Health, Haartmaninkau 1, Helsinki 29, Finland [K. H.]
Binding of the hepatocarcinogen 2-acetylaminofluorene (AAF) and two metabolites, 2-aminofluorene (AF) and N-hydroxy-2-acetylaminofluorene (N-OH-AFF), to the DNA and protein of rat hepatic nuclei was examined in vitro and in a cell-free system. Three and one-half hr following a single injection of each compound in equimolar amounts, DNA contained approximately 50% more of the compounds per mg than did protein. The amount of N-OH-AAF bound to DNA was 4 times greater than that of AAF, while AF bound in intermediate amounts. When incubated with nuclei in a cell-free system, AAF seldom bound in measurable amounts, while significant amounts of N-OH-AAF and AF bound to both DNA and protein. As occurred in vivo, DNA bound more of each per mg than did protein. The amount of N-OH-AFF bound to intranuclear DNA increased 54% when an aliquot of the postmicrosomal liver fraction was added to the incubation mixture, but maximum binding of AF occurred in the absence of any other liver fraction. Thus, it was shown that two AAF metabolites, AF and N-OH-AAF, bind covalently to the DNA and protein of hepatic nuclei more readily than does AAF itself and that binding in a cell-free system parallels binding in vivo. Additional evidence suggests that rat hepatic nuclei are capable of mediating the binding of AF and N-OH-AAF to macromolecules through distinct enzyme systems. This is the first demonstration that the nucleus is capable of metabolizing AF to an electrophile that can bind covalently to DNA.
1 This investigation was supported by Grant CA 20657 awarded by the National Cancer Institute, Department of Health, Education, and Welfare.
2 To whom requests for reprints should be addressed.
Received 5/14/79. Accepted 6/27/80.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |